OSE Immunotherapeutics reported total income of €83.4 million for 2024, with a cash position of €64.2 million ensuring financial visibility until Q1 2027.
The TEDOPaM Phase 2 trial met its primary endpoint, demonstrating that OSE2101 (Tedopi) combined with FOLFIRI chemotherapy achieved a statistically significant improvement in one-year overall survival rate for advanced pancreatic cancer patients.
OSE Immunotherapeutics reported total H1 2024 incomes of €82.5 million, driven by new partnerships with AbbVie and Boehringer Ingelheim, strengthening its financial position.